Posts

Insilico Medicine Receives FDA Fast Track Designation for AI-Driven Pan-TEAD Inhibitor ISM6331 in Advanced Mesothelioma

on

Insilico and Bora Unveil AI-Driven Manufacturing and CDMO Platform Plans

on

Insilico lands heavily backloaded $2.5B AI drug discovery deal with SK Biopharm

on

Human Longevity launches newco, teams with Insilico for AI‑powered longevity research — May 28, 2026 update

on

Insilico's Rentosertib Inhalation Solution Receives IND Clearance for World's First AI-Driven Direct-to-Lung Clinical Study

on

Eli Lilly and Insilico Medicine Announce $2.75 Billion AI-Driven Drug Discovery Collaboration

on

Inside the Race to Build the Next Generation of AI Drug Discovery Platforms

on

Insilico Medicine Secures Nearly $120M AI-Driven Cardiometabolic Drug Deal with Qilu Pharmaceutical

on

Insilico Medicine to Present Three Abstracts on ISM5411 at 2026 Crohn's & Colitis Congress

on

Insilico Medicine to Present Three Abstracts on ISM5411 at 2026 Crohn's & Colitis Congress

on

Insilico Medicine Integrates Nach01 Foundation Model with Microsoft Discovery for AI-Native Drug Discovery

on

Insilico Medicine and Servier Announce Up to $888 Million AI-Driven Oncology R&D Collaboration

on

Insilico Medicine Caps 2025 with Record HKD 2.277 Billion Hong Kong IPO

on

Models are out, molecules are in as AI drug startups sprint to the clinic

on

Insilico Medicine and TaiGen sign exclusive licensing deal for AI-designed PHD inhibitor ISM4808 to treat anemia in chronic kidney disease

on